Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Atherosclerosis

Retrieve available abstracts of 145 articles:
HTML format

Single Articles

    June 2021
  1. RAU M, Thiele K, Korbinian Hartmann NU, Mollmann J, et al
    Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study.
    Atherosclerosis. 2021;330:8-13.
    PubMed     Abstract available

    May 2021
  2. AVERNA M, Banach M, Bruckert E, Drexel H, et al
    Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force.
    Atherosclerosis. 2021;325:99-109.
    PubMed     Abstract available

  3. HEIDEMANN BE, Wolters FJ, Kavousi M, Gruppen EG, et al
    Adiposity and the development of dyslipidemia in APOE epsilon2 homozygous subjects: A longitudinal analysis in two population-based cohorts.
    Atherosclerosis. 2021;325:57-62.
    PubMed     Abstract available

  4. MA F, Darabi M, Lhomme M, Tubeuf E, et al
    Phospholipid transfer to high-density lipoprotein (HDL) upon triglyceride lipolysis is directly correlated with HDL-cholesterol levels and is not associated with cardiovascular risk.
    Atherosclerosis. 2021;324:1-8.
    PubMed     Abstract available

    March 2021
  5. LAMINA C, Kronenberg F
    The causal association of bilirubin with cardiovascular disease: Are there still any questions?
    Atherosclerosis. 2021;320:92-94.

    February 2021
  6. KANEKO H, Itoh H, Kiriyama H, Kamon T, et al
    Fasting plasma glucose and subsequent cardiovascular disease among young adults: Analysis of a nationwide epidemiological database.
    Atherosclerosis. 2021;319:35-41.
    PubMed     Abstract available

    December 2020
  7. HOU L, Li H, Si S, Yu Y, et al
    Exploring the causal pathway from bilirubin to CVD and diabetes in the UK biobank cohort study: Observational findings and Mendelian randomization studies.
    Atherosclerosis. 2020 Dec 8. pii: S0021-9150(20)31566.
    PubMed     Abstract available

    October 2020
  8. NING X, Ding N, Ballew SH, Hicks CW, et al
    Diabetes, its duration, and the long-term risk of abdominal aortic aneurysm: The Atherosclerosis Risk in Communities (ARIC) Study.
    Atherosclerosis. 2020;313:137-143.
    PubMed     Abstract available

    August 2020
  9. SHROFF GR, Sanchez OA, Miedema MD, Kramer H, et al
    Coronary artery calcium progresses rapidly and discriminates incident cardiovascular events in chronic kidney disease regardless of diabetes: The Multi-Ethnic Study of Atherosclerosis (MESA).
    Atherosclerosis. 2020;310:75-82.
    PubMed     Abstract available

    July 2020
  10. AL-MALLAH MH, Hyafil F, Santulli G
    No pleotropic effects of linagliptin on atherosclerotic plaques: Case closed.
    Atherosclerosis. 2020;305:61-63.

    June 2020
  11. SEO DH, Lee YH, Suh YJ, Ahn SH, et al
    Low muscle mass is associated with carotid atherosclerosis in patients with type 2 diabetes.
    Atherosclerosis. 2020;305:19-25.
    PubMed     Abstract available

    April 2020
  12. VIRTA J, Hellberg S, Liljenback H, Stahle M, et al
    Effects of dipeptidyl peptidase 4 inhibition on inflammation in atherosclerosis: A (18)F-fluorodeoxyglucose study of a mouse model of atherosclerosis and type 2 diabetes.
    Atherosclerosis. 2020 Apr 10. pii: S0021-9150(20)30194.
    PubMed     Abstract available

  13. BJERRE M, Hilden J, Winkel P, Jensen GB, et al
    Serum osteoprotegerin as a long-term predictor for patients with stable coronary artery disease and its association with diabetes and statin treatment: A CLARICOR trial 10-year follow-up substudy.
    Atherosclerosis. 2020;301:8-14.
    PubMed     Abstract available

  14. LAUCEVICIUS A, Rinkuniene E, Petrulioniene Z, Ryliskyte L, et al
    Trends in cardiovascular risk factor prevalence among Lithuanian middle-aged adults between 2009 and 2018.
    Atherosclerosis. 2020;299:9-14.
    PubMed     Abstract available

    March 2020
  15. LI B, Luo YR, Tian F, Chen YD, et al
    Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes.
    Atherosclerosis. 2020;300:10-18.
    PubMed     Abstract available

  16. YAO Y, Zhu H, Zhu L, Fang Z, et al
    A comprehensive contribution of genetic variations of the insulin-like growth factor 1 signalling pathway to stroke susceptibility.
    Atherosclerosis. 2020;296:59-65.
    PubMed     Abstract available

  17. ADINOLFI LE, Petta S, Fracanzani AL, Coppola C, et al
    Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study.
    Atherosclerosis. 2020;296:40-47.
    PubMed     Abstract available

  18. LESKELA RL, Torvinen A, Rissanen TT, Virtanen V, et al
    Outcomes of lipid control in secondary prevention of coronary artery disease in Finland: A 24-month follow-up after acute coronary syndrome.
    Atherosclerosis. 2020;296:4-10.
    PubMed     Abstract available

  19. LUNDE NN, Gregersen I, Ueland T, Shetelig C, et al
    Legumain is upregulated in acute cardiovascular events and associated with improved outcome - potentially related to anti-inflammatory effects on macrophages.
    Atherosclerosis. 2020;296:74-82.
    PubMed     Abstract available

    February 2020
  20. HAFNER J, Zierfuss B, Schernthaner GH, Schmidt-Erfurth U, et al
    From the eye into the foot?
    Atherosclerosis. 2020;294:41-43.

    January 2020
  21. CHIU YW, Wu CS, Chen PC, Wei YC, et al
    Risk of acute mesenteric ischemia in patients with diabetes: A population-based cohort study in Taiwan.
    Atherosclerosis. 2020;296:18-24.
    PubMed     Abstract available

  22. CHICHAREON P, Modolo R, Kogame N, Takahashi K, et al
    Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study.
    Atherosclerosis. 2020;295:45-53.
    PubMed     Abstract available

    November 2019
  23. RAMIN-MANGATA S, Wargny M, Pichelin M, Le May C, et al
    Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes.
    Atherosclerosis. 2019;293:49-56.
    PubMed     Abstract available

    October 2019
  24. CATAN A, Turpin C, Diotel N, Patche J, et al
    Aging and glycation promote erythrocyte phagocytosis by human endothelial cells: Potential impact in atherothrombosis under diabetic conditions.
    Atherosclerosis. 2019;291:87-98.
    PubMed     Abstract available

    September 2019
  25. REIJRINK M, de Boer SA, Spoor DS, Lefrandt JD, et al
    Visceral adipose tissue volume is associated with premature atherosclerosis in early type 2 diabetes mellitus independent of traditional risk factors.
    Atherosclerosis. 2019;290:87-93.
    PubMed     Abstract available

    August 2019
  26. WEI W, Li XX, Xu M
    Inhibition of vascular neointima hyperplasia by FGF21 associated with FGFR1/Syk/NLRP3 inflammasome pathway in diabetic mice.
    Atherosclerosis. 2019;289:132-142.
    PubMed     Abstract available

    July 2019
  27. MORELLI MB, Wang X, Santulli G
    Functional role of gut microbiota and PCSK9 in the pathogenesis of diabetes mellitus and cardiovascular disease.
    Atherosclerosis. 2019 Jul 30. pii: S0021-9150(19)31425.

  28. KABOOTARI M, Hasheminia M, Guity K, Ramezankhani A, et al
    Gestational diabetes mellitus in mothers and long term cardiovascular disease in both parents: Results of over a decade follow-up of the Iranian population.
    Atherosclerosis. 2019;288:94-100.
    PubMed     Abstract available

  29. BARCHUK M, Schreier L, Lopez G, Cevey A, et al
    Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 and angiopoietin-like protein 4 are associated with the increase of lipoprotein lipase activity in epicardial adipose tissue from diabetic patients.
    Atherosclerosis. 2019;288:51-59.
    PubMed     Abstract available

  30. ANHOLM C, Kumarathurai P, Pedersen LR, Samkani A, et al
    Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
    Atherosclerosis. 2019;288:60-66.
    PubMed     Abstract available

    June 2019
  31. QIU S, Cai X, Liu J, Yang B, et al
    Association between circulating cell adhesion molecules and risk of type 2 diabetes: A meta-analysis.
    Atherosclerosis. 2019;287:147-154.
    PubMed     Abstract available

    May 2019
  32. DE SILVA GS, Desai K, Darwech M, Naim U, et al
    Circulating serum fatty acid synthase is elevated in patients with diabetes and carotid artery stenosis and is LDL-associated.
    Atherosclerosis. 2019;287:38-45.
    PubMed     Abstract available

  33. KOWALL B, Stang A
    Reply to: "Methodological issues regarding "Decline in ankle-brachial index is stronger in poorly than in well controlled diabetes: Results from the Heinz Nixdorf Recall cohort study"".
    Atherosclerosis. 2019 May 4. pii: S0021-9150(19)30401.

    April 2019
    Methodological issues regarding "Decline in ankle-brachial index is stronger in poorly than in well controlled diabetes: Results from the Heinz Nixdorf Recall cohort study".
    Atherosclerosis. 2019 Apr 17. pii: S0021-9150(19)30382.

  35. CHEN Y, Dong J, Zhang X, Chen X, et al
    Evacetrapib reduces prebeta-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes.
    Atherosclerosis. 2019;285:147-152.
    PubMed     Abstract available

  36. RAO AD, Vaz CL, Williams KJ
    Accelerated atherosclerotic cardiovascular risk in type 1 diabetes mellitus: Time for a new idea?
    Atherosclerosis. 2019 Apr 14. pii: S0021-9150(19)30362.

    March 2019
  37. SCHERNTHANER GH, Rami-Merhar B, Zierfuss B
    Gestational diabetes and maternal obesity suggestively priming children's premature atherosclerosis: Is it the mother fault?
    Atherosclerosis. 2019 Mar 4. pii: S0021-9150(19)30115.

  38. HAGENSEN MK, Mortensen MB, Kjolby M, Palmfeldt J, et al
    Increased retention of LDL from type 1 diabetic patients in atherosclerosis-prone areas of the murine arterial wall.
    Atherosclerosis. 2019 Mar 4. pii: S0021-9150(19)30114.
    PubMed     Abstract available

  39. KOWALL B, Erbel R, Moebus S, Lehmann N, et al
    Decline in ankle-brachial index is stronger in poorly than in well controlled diabetes: Results from the Heinz Nixdorf Recall cohort study.
    Atherosclerosis. 2019;284:37-43.
    PubMed     Abstract available

    February 2019
  40. SUNDHOLM JKM, Litwin L, Rono K, Koivusalo SB, et al
    Maternal obesity and gestational diabetes: Impact on arterial wall layer thickness and stiffness in early childhood - RADIEL study six-year follow-up.
    Atherosclerosis. 2019 Feb 12. pii: S0021-9150(19)30064.
    PubMed     Abstract available

    January 2019
  41. LIU X, Li J, Liao J, Wang H, et al
    Gpihbp1 deficiency accelerates atherosclerosis and plaque instability in diabetic Ldlr(-/-) mice.
    Atherosclerosis. 2019;282:100-109.
    PubMed     Abstract available

    December 2018
  42. SAEED A, Sun W, Agarwala A, Virani SS, et al
    Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study.
    Atherosclerosis. 2018;282:52-56.
    PubMed     Abstract available

  43. WAKE M, Oh A, Onishi Y, Guelfucci F, et al
    Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan.
    Atherosclerosis. 2018;282:19-28.
    PubMed     Abstract available

  44. ZHAO Y, Evans MA, Allison MA, Bertoni AG, et al
    Multisite atherosclerosis in subjects with metabolic syndrome and diabetes and relation to cardiovascular events: The Multi-Ethnic Study of Atherosclerosis.
    Atherosclerosis. 2018 Dec 15. pii: S0021-9150(18)31525.
    PubMed     Abstract available

    November 2018
  45. BOJANIN D, Vekic J, Milenkovic T, Vukovic R, et al
    Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control.
    Atherosclerosis. 2018;280:14-20.
    PubMed     Abstract available

  46. GUO J, Nunley KA, Costacou T, Miller RG, et al
    Greater progression of coronary artery calcification is associated with clinically relevant cognitive impairment in type 1 diabetes.
    Atherosclerosis. 2018;280:58-65.
    PubMed     Abstract available

    October 2018
  47. SAELY CH, Schindewolf M, Zanolin D, Heinzle CF, et al
    Single and combined effects of peripheral artery disease and of type 2 diabetes mellitus on the risk of cardiovascular events: A prospective cohort study.
    Atherosclerosis. 2018;279:32-37.
    PubMed     Abstract available

    September 2018
  48. BARTER PJ, Cochran BJ, Rye KA
    CETP inhibition, statins and diabetes.
    Atherosclerosis. 2018;278:143-146.
    PubMed     Abstract available

    August 2018
  49. BYUN JK, Choi BG, Rha SW, Choi SY, et al
    Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention.
    Atherosclerosis. 2018;277:130-135.
    PubMed     Abstract available

  50. MA M, Hui J, Zhang QY, Zhu Y, et al
    Long non-coding RNA nuclear-enriched abundant transcript 1 inhibition blunts myocardial ischemia reperfusion injury via autophagic flux arrest and apoptosis in streptozotocin-induced diabetic rats.
    Atherosclerosis. 2018;277:113-122.
    PubMed     Abstract available

  51. MUNOZ-HERNANDEZ L, Ortiz-Bautista RJ, Brito-Cordova G, Lozano-Arvizu F, et al
    Cholesterol efflux capacity of large, small and total HDL particles is unaltered by atorvastatin in patients with type 2 diabetes.
    Atherosclerosis. 2018;277:72-79.
    PubMed     Abstract available

    July 2018
  52. TASKINEN MR, Del Prato S, Bujas-Bobanovic M, Louie MJ, et al
    Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial.
    Atherosclerosis. 2018;276:124-130.
    PubMed     Abstract available

  53. PALANCA A, Castelblanco E, Perpinan H, Betriu A, et al
    Prevalence and progression of subclinical atherosclerosis in patients with chronic kidney disease and diabetes.
    Atherosclerosis. 2018;276:50-57.
    PubMed     Abstract available

  54. PAN HC, Chou KM, Lee CC, Yang NI, et al
    Circulating Klotho levels can predict long-term macrovascular outcomes in type 2 diabetic patients.
    Atherosclerosis. 2018;276:83-90.
    PubMed     Abstract available

  55. HEIER M, Ofstad AP, Borja MS, Brunborg C, et al
    High-density lipoprotein function is associated with atherosclerotic burden and cardiovascular outcomes in type 2 diabetes.
    Atherosclerosis. 2018 Jul 6. pii: S0021-9150(18)31201.
    PubMed     Abstract available

    June 2018
  56. MIETTINEN HE, Rono K, Koivusalo SB, Eriksson JG, et al
    Effect of gestational diabetes mellitus on newborn cholesterol metabolism.
    Atherosclerosis. 2018;275:346-351.
    PubMed     Abstract available

    May 2018
  57. MANCINI GBJ, Boden WE, Brooks MM, Vlachos H, et al
    Impact of treatment strategies on outcomes in patients with stable coronary artery disease and type 2 diabetes mellitus according to presenting angina severity: A pooled analysis of three federally-funded randomized trials.
    Atherosclerosis. 2018 May 31. pii: S0021-9150(18)30179.
    PubMed     Abstract available

  58. SUNG KC, Lee MY, Kim YH, Huh JH, et al
    Obesity and incidence of diabetes: Effect of absence of metabolic syndrome, insulin resistance, inflammation and fatty liver.
    Atherosclerosis. 2018;275:50-57.
    PubMed     Abstract available

  59. COLOMBO M, Looker HC, Farran B, Agakov F, et al
    Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes.
    Atherosclerosis. 2018;274:182-190.
    PubMed     Abstract available

  60. RAGGI P
    Angina severity, therapeutic choices and outcome in patients with diabetes mellitus.
    Atherosclerosis. 2018 May 3. pii: S0021-9150(18)30223.

    April 2018
  61. WILCOX T, Newman JD, Maldonado TS, Rockman C, et al
    Peripheral vascular disease risk in diabetic individuals without coronary heart disease.
    Atherosclerosis. 2018 Apr 30. pii: S0021-9150(18)30211.
    PubMed     Abstract available

  62. MACEDONI M, Hovnik T, Plesnik E, Kotnik P, et al
    Metabolic control, ApoE genotypes, and dyslipidemia in children, adolescents and young adults with type 1 diabetes.
    Atherosclerosis. 2018;273:53-58.
    PubMed     Abstract available

    March 2018
  63. SUAREZ-ORTEGON MF, McLachlan S, Price AH, Fernandez-Balsells M, et al
    Decreased iron stores are associated with cardiovascular disease in patients with type 2 diabetes both cross-sectionally and longitudinally.
    Atherosclerosis. 2018;272:193-199.
    PubMed     Abstract available

  64. AL-SHAREA A, Murphy AJ, Huggins LA, Hu Y, et al
    SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr(-/-) type 1 diabetic mice.
    Atherosclerosis. 2018;271:166-176.
    PubMed     Abstract available

  65. SINIARSKI A, Haberka M, Mostowik M, Golebiowska-Wiatrak R, et al
    Treatment with omega-3 polyunsaturated fatty acids does not improve endothelial function in patients with type 2 diabetes and very high cardiovascular risk: A randomized, double-blind, placebo-controlled study (Omega-FMD).
    Atherosclerosis. 2018;271:148-155.
    PubMed     Abstract available

    February 2018
  66. RAGGI P
    Atherosclerosis imaging to refine cardiovascular risk assessment in diabetic patients: Computed tomography and positron emission tomography applications.
    Atherosclerosis. 2018;271:77-83.
    PubMed     Abstract available

    December 2017
  67. LIGHTELL DJ JR, Moss SC, Woods TC
    Upregulation of miR-221 and -222 in response to increased extracellular signal-regulated kinases 1/2 activity exacerbates neointimal hyperplasia in diabetes mellitus.
    Atherosclerosis. 2017;269:71-78.
    PubMed     Abstract available

  68. TORRES-PENA JD, Garcia-Rios A, Delgado-Casado N, Gomez-Luna P, et al
    Mediterranean diet improves endothelial function in patients with diabetes and prediabetes: A report from the CORDIOPREV study.
    Atherosclerosis. 2017;269:50-56.
    PubMed     Abstract available

    November 2017
  69. CHRISTODOULOU E, Kadoglou NPE, Stasinopoulou M, Konstandi OA, et al
    Crocus sativus L. aqueous extract reduces atherogenesis, increases atherosclerotic plaque stability and improves glucose control in diabetic atherosclerotic animals.
    Atherosclerosis. 2017 Nov 1. pii: S0021-9150(17)31370.
    PubMed     Abstract available

    October 2017
  70. GANJALI S, Dallinga-Thie GM, Simental-Mendia LE, Banach M, et al
    HDL functionality in type 1 diabetes.
    Atherosclerosis. 2017;267:99-109.
    PubMed     Abstract available

    September 2017
  71. MARCADENTI A, Fuchs FD, Moreira LB, Gus M, et al
    Adiposity phenotypes are associated with type-2 diabetes: LAP index, body adiposity index, and neck circumference.
    Atherosclerosis. 2017;266:145-150.
    PubMed     Abstract available

    August 2017
  72. SCHMIDT N, Schmidt B, Dressel A, Gergei I, et al
    Familial hypercholesterolemia in primary care in Germany. Diabetes and cardiovascular risk evaluation: Targets and Essential Data for Commitment of Treatment (DETECT) study.
    Atherosclerosis. 2017;266:24-30.
    PubMed     Abstract available

  73. CAMARGO GARCIA A, Garcia-Carpintero S, Lopez-Moreno J, Jimenez-Lucena R, et al
    Postprandial endotoxemia may influence the type 2 diabetes mellitus development.
    Atherosclerosis. 2017;263:e98.

  74. STECHOVA K, Sklenarova J, Kratzerova T, Filipp D, et al
    Association between immune and lipid factors in women with diabetes type 1.
    Atherosclerosis. 2017;263:e97-e98.

  75. EL KHOURY P, Roussel R, Fumeron F, Velho G, et al
    Plasma PCSK9 and cardiovascular events in type 2 diabetes.
    Atherosclerosis. 2017;263:e81.

  76. WITKOWSKI M, Weithauser A, Tabaraie T, Steffens D, et al
    Endothelial micrornas epigenetically control vascular inflammation and thrombogenicity in diabetes.
    Atherosclerosis. 2017;263:e76.

  77. SUN Y, Kopp S, Gali CC, Zandl M, et al
    Gestational diabetes mellitus modulates cholesterol metabolism in human fetoplacental endothelial cells.
    Atherosclerosis. 2017;263:e74-e75.

  78. WALUS-MIARKA M, Idzior-Walus B, Trojak A, Kapusta M, et al
    Pentraxin 3 concentration in patients with type 2 diabetes mellitus and NAFLD.
    Atherosclerosis. 2017;263:e54.

  79. PITHOVA P, Pitha J, Stechova K, Kvapil M, et al
    Preclinical atherosclerosis is associated with insulin resistance in type 1 diabetes women.
    Atherosclerosis. 2017;263:e54.

  80. IHM SH, Lee KY, Kim JJ, Hwang BH, et al
    CT Angiography-imaged coronary artery stenosis provides better risk prediction than traditional risk factors in asymptomatic diabetic individuals: A long-term study of clinical outcomes.
    Atherosclerosis. 2017;263:e53.

  81. ILYAS Z, Al-Ghamdi J, Nguan-Soon T, Kiss-Toth E, et al
    Tribbles-3, a regulator of metabolic syndromes and type 2 diabetes.
    Atherosclerosis. 2017;263:e50.

  82. CAVALCANTE MARANHAO R, Franca Marques A, Guido MC, Rufo Tavares E, et al
    Effects of treatment with methotrexate associated to lipid nanoparticles on diabetic cardiomyopathy in rats.
    Atherosclerosis. 2017;263:e48.

  83. STOJIC I, Tepic S, Petkovic A, Srejovic I, et al
    Time dependent effects of hbot on redox status in diabetic patients.
    Atherosclerosis. 2017;263:e276.

  84. MANEA V, Pop C, Pop L
    Correlations of dipper profiles in diabetic patients with hypertension: the importance of ambulatory blood pressure monitoring/24 hours.
    Atherosclerosis. 2017;263:e276.

  85. KYRIAZIS I, Sgouros K, Stefani D, Vallianou K, et al
    The effect of the presence and the level of dyslipidemia control on diabetic patients with first acute ischemic stroke.
    Atherosclerosis. 2017;263:e275-e276.

  86. PITHA J, Pithova P, Roztocil K, Urbaniec K, et al
    Oliva-roztocil index, specific parameter of vascular damage in women suffering from diabetes mellitus.
    Atherosclerosis. 2017;263:e275.

  87. KUMAR N, Khanna RK
    Anti-diabetic effect of trigonella foenum greacum seed acetone fraction in a type 2 diabetes model of rats.
    Atherosclerosis. 2017;263:e273.

  88. BAUDIN B, Nekaies Y, Baudin B, Kelbousi S, et al
    Association of apolipoproteins plasma levels with PCSK9 in type 2 diabetes mellitus.
    Atherosclerosis. 2017;263:e273-e274.

  89. RAJPUT S, Sinha S
    Modulation of the coexistence of diabetes and hypothyroidism on body weight gain, leptin and various metabolic aspects in wistar rats.
    Atherosclerosis. 2017;263:e272.

  90. DIOSZEGI A, Vass M, Nemeth N, Sogor V, et al
    Rheopheresis treatment of diabetic foot syndrome.
    Atherosclerosis. 2017;263:e272.

  91. NANASY-VASS M, Dioszegi A, Flasko A, Mechler F, et al
    Study of microcirculatory impairment in type 2 diabetic patients with symptoms of peripherial neuropathy.
    Atherosclerosis. 2017;263:e272-e273.

  92. SHALAEVA E, Janabaev B, Bobabekov A, Kasimov U, et al
    Coronary computed tomographic angiography and coronary artery calcium score in patients with type 2 diabetes undergoing trans-femoral amputation in 2013 in different clinical groups.
    Atherosclerosis. 2017;263:e271-e272.

  93. ENA J, Perez S, Alvarez CE, Valls V, et al
    Triglyceride to high density lipoprotein cholesterol ratio, total cholesterol to high density lipoprotein cholesterol ratio and low ankle brachial index in patients with diabetes.
    Atherosclerosis. 2017;263:e270.

  94. ENA J, Perez S, Argente CR, Lozano T, et al
    Systolic blood pressure difference between arms and peripheral arterial disease in patients with diabetes mellitus.
    Atherosclerosis. 2017;263:e270-e271.

  95. ZIVKOVIC V, Vranic A, Simovic S, Ristic P, et al
    The acute effects of different spironolactone doses on cardiac function in streptozotocine-induced diabetic rats.
    Atherosclerosis. 2017;263:e268-e270.

  96. DUARTE JS, Bello C, Ferreira R, Limbert C, et al
    Atherogenic dislipidemia in patients with type 2 diabetes linked to microvascular complications and heart disease.
    Atherosclerosis. 2017;263:e265.

  97. ZHILINA S, Miramontes Gonzalez JP, Laso Guzman FJ
    Familial hypercholesterolemia and the diabetogenic effect of statins.
    Atherosclerosis. 2017;263:e264.

  98. BENEDI MVM, Calahorra SP, Sanz AMB, Baila Rueda L, et al
    A randomized, open-label study to investigate the effect of a high protein diet compared to a normoprotein diet on hydrocarbon metabolism in patients with diabetes or prediabetes and obesity.
    Atherosclerosis. 2017;263:e263.

  99. NIKOLOVA A, Milanova M, Stoyanov K, Yankov G, et al
    Risk assessment for diabetes mellitus type 2 in women.
    Atherosclerosis. 2017;263:e263-e264.

  100. SZTANEK F, Seres I, Lorincz H, Molnar A, et al
    Effect of alpha-lipoic acid supplementation on oxidative stress markers and antioxidative defense in patients with diabetic neuropathy.
    Atherosclerosis. 2017;263:e263.

  101. CASULA M, Mozzanica F, Scotti L, Tragni E, et al
    Statin use and risk of new-onset diabetes: a meta-analysis of observational studies.
    Atherosclerosis. 2017;263:e262-e263.

  102. DOULAMIS I, Tzani A, Konstantopoulos P, Antoranz A, et al
    Targeted proteomics identification of biomarkers for diabetes mellitus in patients with cardiovascular disease.
    Atherosclerosis. 2017;263:e261.

  103. PARAGH G, Lorincz H, Somodi S, Varga VE, et al
    Serum afamin level is strongly associated to the components of metabolic syndrome in non-diabetic obese patients.
    Atherosclerosis. 2017;263:e261.

  104. OVSYANNIKOVA A, Rymar O, Shaksthneider E, Ragino Y, et al
    The prevalence of dyslipidemia in young patients with diabetes mellitus.
    Atherosclerosis. 2017;263:e260-e261.

  105. OVSYANNIKOVA A, Rymar O, Shaksthneider E, Voevoda M, et al
    Clinical case: The development of atherosclerosis in a patient 28 years old with 12 mody diabetes.
    Atherosclerosis. 2017;263:e260.

  106. BARKAS F, Elisaf M, Liberopoulos E, Liamis G, et al
    Metabolic markers to predict incident diabetes in statin-treated individuals.
    Atherosclerosis. 2017;263:e259.

  107. SHAKHTSHNEIDER E, Ovsyannikova A, Ivanoshchuk D, Rymar O, et al
    The spectrum of mutations in the CEL gene in early onset diabetes patients.
    Atherosclerosis. 2017;263:e259-e260.

  108. GARCIA-DONAIRE JA, Franch-Nadal J, Rodriguez-Fortunez P, Labrador-Barba E, et al
    The importance of the training as an integral part of caring for the diabetic patient. FORMA2 study: Differences between urban and rural work area.
    Atherosclerosis. 2017;263:e258.

  109. SHALIMOVA A, Bilovol O, Bobronnikova L
    Severity of cardiovascular remodeling in comorbidity of essential hypertension and type 2 diabetes depending on genetic polymorphism of AGTR1 and IRS-1.
    Atherosclerosis. 2017;263:e258.

  110. HAN Y, Jang YN, Lee YJ, Kim HM, et al
    Fimasartan nomalizes carbohydrate metabolism through AMPK pathway in diabetic condition.
    Atherosclerosis. 2017;263:e258-e259.

  111. VONBANK A, Zanolin D, Leiherer A, Rein P, et al
    The power of thyroid stimulating hormone to predict cardiovascular mortality in non-obese patients is significantly modulated by type 2 diabetes.
    Atherosclerosis. 2017;263:e256.

  112. SAELY C, Vonbank A, Zanolin D, Leiherer A, et al
    Single and joint effects of obesity and of the metabolic syndrome on the development of diabetes in patients with coronary atherosclerosis.
    Atherosclerosis. 2017;263:e256.

  113. SAELY C, Rein P, Leiherer A, Vonbank A, et al
    Remnant cholesterol predicts the development of type 2 diabetes mellitus in patients with established coronary artery disease.
    Atherosclerosis. 2017;263:e256.

  114. SAELY C, Zanolin D, Rein P, Leiherer A, et al
    Concordance of glucose-based and of HbA1c-based diagnoses of diabetes in patients with peripheral arterial disease-a comparison between men and women.
    Atherosclerosis. 2017;263:e255.

  115. SAELY C, Zanolin D, Vonbank A, Leiherer A, et al
    Non-alcoholic fatty liver disease strongly predicts incident diabetes in patients with coronary artery disease.
    Atherosclerosis. 2017;263:e255-e256.

  116. DEMIKHOVA N, Chernatska O, Smiianova O, Vynnychenko L, et al
    The correlation between polimorphism of CYP7a1 gene and glycated hemoglobin in hypertensive patients with type 2 diabetes mellitus.
    Atherosclerosis. 2017;263:e254.

  117. KIM BJ, Han JM, Do JH, Kim BS, et al
    Sex-specific relationship between cotinine-verified second-hand smoke exposure and diabetes in 85,697 never-smokers.
    Atherosclerosis. 2017;263:e254.

  118. EISENGA M, Zelle D, Sloan J, Gaillard C, et al
    High serum PCSK9 is associated with increased risk of new-onset diabetes after transplantation in renal transplant recipients.
    Atherosclerosis. 2017;263:e254-e255.

    Effect of canagliflozin on visceral fat area and heart rate in patients with type 2 diabetes mellitus.
    Atherosclerosis. 2017;263:e252.

  120. FULOP P, Seres I, Lorincz H, Somodi S, et al
    Lipocalin 2 may be a potential biomarker of atherosclerotic complications in obese non-diabetic individuals.
    Atherosclerosis. 2017;263:e250.

  121. SZENTPETERI A, Lorincz H, Somodi S, Varga VE, et al
    Human obestatin level and its correlations with metabolic syndrome components in non-diabetic obese patients.
    Atherosclerosis. 2017;263:e250.

  122. KARASEK D, Gajdova J, Kubickova V, Krystynik O, et al
    Selected adipokines in patients with type 2 diabetes: Relationship to soluble markers of endothelial dysfunction-a pilot study.
    Atherosclerosis. 2017;263:e249.

  123. ASKRI I, Kelbousi S, Sakly M, Attia N, et al
    Atorvastatin effect on phospholipid profile and distribution between lipoprotein fractions in type 2 diabetic patients with and without CAD.
    Atherosclerosis. 2017;263:e246.

  124. YASUDA H, Fujiwara A, Komiya S, Haze T, et al
    Effects of rosuvastatin add-on treatment on hyperlipidemia in type 2 diabetic patients with chronic kidney disease receiving ethyl icosapentate.
    Atherosclerosis. 2017;263:e241-e242.

  125. BATURINA O, Mironova O
    Clinical case of hyperlipidemia type IV in a man with diabetes, myocardial infarction and stroke.
    Atherosclerosis. 2017;263:e227-e228.

  126. MAGLAPHERIDZE Z, Tabukashvili R, Kapetivadze V, Tchaava K, et al
    Treatment of dyslipidemia in diabetic type 2 patients with hypertension.
    Atherosclerosis. 2017;263:e217.

  127. MARANHAO RC, Tavoni TM, Laverdy Neto OG, Sprandel MDCO, et al
    Differences in lipid transfers to HDL between patients with coronary arterial disease with or without type 2 diabetes mellitus.
    Atherosclerosis. 2017;263:e217.

  128. ARAGONA CO, Cairo V, Scuruchi M, Giunta L, et al
    Evaluation of Lp(a) and insulin during pregnancy in not diabetic women. Preliminary data.
    Atherosclerosis. 2017;263:e208.

  129. WALUS-MIARKA M, Trojak A, Kapusta M, Idzior-Walus B, et al
    Pentraxin 3 concentration is positively associated with apo C3 and abdominal obesity in men with type 2 diabetes.
    Atherosclerosis. 2017;263:e207.

  130. VASILKOVA V, Mokhort T, Naumenko E, Zmailik M, et al
    Association between systolic dysfunction and inflammation in diabetic patients with chronic kidney disease.
    Atherosclerosis. 2017;263:e191.

  131. LAKHOUA Y, Ben Nacef I, Bouzid K, M'Chrirgui N, et al
    Prevalence of diabetes and frequency of cardiovascular risk factors in paramedical and administrative staff of Charles Nicolle hospital.
    Atherosclerosis. 2017;263:e180-e181.

  132. VONBANK A, Saely C, Rein P, Leiherer A, et al
    The visceral adiposity index predicts cardiovascular events both in coronary artery disease patients with and in coronary artery disease patients without diabetes.
    Atherosclerosis. 2017;263:e172-e173.

  133. VIKULOVA O, Bolotskaya L, Bessmertnaya E, Artemova E, et al
    Frequency of diabetic complications and HbA1C level by active screening and diabetes registry data: Comparative study.
    Atherosclerosis. 2017;263:e171.

  134. KONSTANTOPOULOS P, Tzani A, Doulamis IP, Korou ML, et al
    Anti-inflammatory, hypolipidemic and hepatoprotective properies of CMG in an experimental model of diabetes.
    Atherosclerosis. 2017;263:e166-e167.

  135. REVNIC CR, Revnic F, Pena C, Nica AS, et al
    The role of physical training on neuroendocrine axis, physiology and metabolism in elderly with/without diabetes.
    Atherosclerosis. 2017;263:e161.

  136. KUMAR S, Sharma V
    Hypertension, obesity, diabetes, and heart failure-free survival: The cardiovascular disease lifetime risk pooling project in New Delhi, India.
    Atherosclerosis. 2017;263:e159.

  137. NOVAKOVIC R, Cirovic S, Markovic-Lipkovski J, Rajkovic J, et al
    Effect of polyphenol resveratrol on the isolated renal artery of normal and diabetic rats.
    Atherosclerosis. 2017;263:e157.

  138. STOJANOVIC M, Radenkovic M
    Clarification of serotonin-induced effects in peripheral artery disease via the rat femoral artery response in models of diabetes and vascular occlusion.
    Atherosclerosis. 2017;263:e133-e134.

  139. RAJKOVIC J, Peric M, Stanisic J, Rakocevic J, et al
    Involvement of ATP-sensitive potassium channels in effect of pinacidil on saphenous vein obtained from the patients with and without type 2 diabetes mellitus.
    Atherosclerosis. 2017;263:e131.

  140. NIKOLOV A, Tsinlikov I, Tsinlikova I, Nicoloff G, et al
    Levels of anti-elastin IgA antibodies are associated with high risk of atherosclerosis in diabetics with essential hypertension.
    Atherosclerosis. 2017;263:e124-e125.

  141. MELNIKOV I, Gabbasov Z, Kozlov S, Byazrova S, et al
    Assessment of novel biomarkers for restenosis occurrence after drug-eluting stent implantation in patients with stable coronary artery disease and type 2 diabetes mellitus.
    Atherosclerosis. 2017;263:e121-e122.

  142. VIRTA J, Silvola J, Hellberg S, Stahle M, et al
    Effects of linagliptin intervention on atherosclerotic plaque inflammation and 18F-FDG uptake in a mouse model of type 2 diabetes.
    Atherosclerosis. 2017;263:e119-e120.

  143. PETELINA T, Musikhina N, Gapon L, Emeneva I, et al
    Features of atherogenic lipid profile and inflammatory markers in patients with stable angina and type 2 diabetes mellitus.
    Atherosclerosis. 2017;263:e118.

  144. KULIKOWSKI E, Calosing C, Tsujikawa L, Wasiak S, et al
    Apabetalone (RVX-208) may lower CVD events in diabetes mellitus by affecting complement pathway and microbiome activity.
    Atherosclerosis. 2017;263:e113.

  145. POVLSEN GK, Langhi C, Skytte Olsen G
    Regulation of hepatic LDL-receptor and PCSK9 expression by insulin in diabetic mice and in vitro in hepatocyte models.
    Atherosclerosis. 2017;263:e102.

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.